Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 1/20 | 0.50 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GSTA1 | P08263 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116115 | 0.88 | PARK7 (0.53) | PARK7GAAMAPTKMT2ANPC1 | |
| SCHEMBL666050 | 0.86 | PARK7 (0.50) | PARK7TMPRSS4PLAUF2F10 | |
| SCHEMBL666185 | 0.86 | P2RX1 (0.51) | PARK7TMPRSS4KMT2AMEN1P2RX1 | |
| Dehydroxymethylepoxyquinomicin SCHEMBL1671089 | 0.84 | PARK7 (0.54) | PARK7HPGDGAAMAPTKMT2A | |
| Dehydroxymethylepoxyquinomicin SCHEMBL14491796 | 0.84 | PARK7 (0.54) | PARK7HPGDGAAMAPTKMT2A | |
| Dehydroxymethylepoxyquinomicin SCHEMBL1669417 | 0.84 | PARK7 (0.54) | PARK7HPGDGAAMAPTKMT2A | |
| Dehydroxymethylepoxyquinomicin SCHEMBL14504317 | 0.84 | PARK7 (0.54) | PARK7HPGDGAAMAPTKMT2A | |
| SCHEMBL666087 | 0.82 | PARK7 (0.64) | PARK7PLAUF2F10PLAT | |
| SCHEMBL665474 | 0.81 | PARK7 (0.49) | PARK7TMPRSS4MAPTKMT2ANPC1 | |
| SCHEMBL666528 | 0.79 | PARK7 (0.50) | PARK7PLAUF2F10PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | PROFECTUS BIOSCIENCES, INC. (US) | 2012-02-23 | — | — | US | claimed |
| EP-2424850-A1 | BENZAMIDE AND NAPHTHAMIDE DERIVATIVES INHIBITING NUCLEAR FACTOR- KAP PA (B) - (NF-KB) | Profectus Biosciences, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | PROFECTUS BIOSCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010127058-A1 | BENZAMIDE AND NAPHTHAMIDE DERIVATIVES INHIBITING NUCLEAR FACTOR- KAP PA (B) - (NF-KB) | PROFECTUS BIOSCIENCES, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | NFKBIA, IKBKB, NFKB1 | PARK7 3384/4885TMPRSS4 2798/4885PLAU 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.